Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR3 | P25089 | 4/20 | 0.33 |
| ▸ | FPR2 | P25090 | 4/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485802 | 0.85 | CHRNB2 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4USP30 | |
| SCHEMBL6499195 | 0.85 | SMYD3 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4USP30 | |
| SCHEMBL6500752 | 0.80 | USP30 (0.52) | USP30 | |
| SCHEMBL6491156 | 0.79 | USP30 (0.41) | USP30 | |
| SCHEMBL6498845 | 0.78 | ALDH1A1 (0.51) | — | |
| SCHEMBL6486393 | 0.78 | USP30 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4USP30 | |
| SCHEMBL6486763 | 0.78 | HDAC1 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4USP30 | |
| SCHEMBL6501682 | 0.78 | USP30 (0.43) | USP30 | |
| SCHEMBL6502161 | 0.78 | HDAC1 (0.43) | USP30 | |
| SCHEMBL6490592 | 0.77 | USP30 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | claimed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | claimed |
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | MALT1, WFS1, NR5A1 | FPR3 1972/4885FPR2 1456/4885CHRNB2 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.